In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.

NCT Number	NCT07239323
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
Enrollment	24 participants
Start Date	2025-07-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-20